title: Choroidal neovascularization in angioid streaks and pseudoxanthoma elasticum: 1 year follow-up.
abstract: OBJECTIVE
  To report the efficacy of intravitreal injection of bevacizumab 1.25 mg (IVB) in the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS).
  
  
  METHODS
  Case review of two patients with CNV secondary to AS treated with three IVB with a 1-year follow up.
  
  
  RESULTS
  In both patients after 1 year fluorescein angiography and optical coherence tomography showed complete inactivity of the CNV and the ophthalmologic examination revealed stabilization of the visual acuity.
  
  
  CONCLUSIONS
  The IBV appeared to be an effective and safe treatment for CNV secondary to AS resulting in a long-term CNV inactivation. Further long-term studies in this type of lesion are desirable.
authors.affiliation: Fondazione G.B. Bietti-IRCCS, Roma, Italy. dodoschiano@libero.it
authors.forename: D
authors.initials: D
authors.lastname: Schiano Lomoriello
authors.forename: M C
authors.initials: MC
authors.lastname: Parravano
authors.forename: A
authors.initials: A
authors.lastname: Chiaravalloti
authors.forename: M
authors.initials: M
authors.lastname: Varano
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000793:Angioid Streaks / Q000150:complications* / Q000175:diagnosis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D011561:Pseudoxanthoma Elasticum / Q000150:complications* / Q000175:diagnosis; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab